Compounded tirzepatide — current market analysis

Dr.EM_Chicago said:

The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

That is correct as far as it goes, and here is where it stops going. Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces a significant clinical difference for that patient. A grid of fixed doses offered to everybody is not that, whatever the intake form says.

pete_nash said:

Agreed on the mechanism, with the caveat that the head-to-head used semaglutide 1mg, not 2.4mg.

This answered a question I did not know how to ask.

Dr.EM_Chicago said:

The shortage clause is the answer to the second question and it is a subtraction rather than an addition.

This is where I part company with the consensus forming above. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

Adding the numbers, since they settle part of this. One practical note: write down what you did and when, before you need it. Reconstructing a timeline from memory three months later is how people end up unable to answer the one question that would have resolved it.

Moderator note: a couple of off-topic posts removed. Carry on.